TP53 and acute myeloid leukemia: In the R/R AML cohort, univariate analysis indicated that CR/CRi was associated with improved survival, whereas adverse cytogenetics, DNMT3A, ASXL1, and TP53 mutations were associated with inferior survival (Table S7).